FR2274314A1 - Incorporation of BCG into viral vaccines - in order to increase the immunising power of the vaccine - Google Patents

Incorporation of BCG into viral vaccines - in order to increase the immunising power of the vaccine

Info

Publication number
FR2274314A1
FR2274314A1 FR7420376A FR7420376A FR2274314A1 FR 2274314 A1 FR2274314 A1 FR 2274314A1 FR 7420376 A FR7420376 A FR 7420376A FR 7420376 A FR7420376 A FR 7420376A FR 2274314 A1 FR2274314 A1 FR 2274314A1
Authority
FR
France
Prior art keywords
bcg
vaccine
immunising
incorporation
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7420376A
Other languages
French (fr)
Other versions
FR2274314B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
METIANU TIBERE
Original Assignee
METIANU TIBERE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by METIANU TIBERE filed Critical METIANU TIBERE
Priority to FR7420376A priority Critical patent/FR2274314A1/en
Publication of FR2274314A1 publication Critical patent/FR2274314A1/en
Application granted granted Critical
Publication of FR2274314B1 publication Critical patent/FR2274314B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A new vaccine comprises a mixt. of living BCG bacilli, a living viral vaccine which is attenuated or inactivated, and antitoxins. It is administered in a single dose to confer a prophylacetic effect to man and animals. The presence of the BCG increases the activity of the viral vacinne.
FR7420376A 1974-06-12 1974-06-12 Incorporation of BCG into viral vaccines - in order to increase the immunising power of the vaccine Granted FR2274314A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7420376A FR2274314A1 (en) 1974-06-12 1974-06-12 Incorporation of BCG into viral vaccines - in order to increase the immunising power of the vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7420376A FR2274314A1 (en) 1974-06-12 1974-06-12 Incorporation of BCG into viral vaccines - in order to increase the immunising power of the vaccine

Publications (2)

Publication Number Publication Date
FR2274314A1 true FR2274314A1 (en) 1976-01-09
FR2274314B1 FR2274314B1 (en) 1978-07-21

Family

ID=9139963

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7420376A Granted FR2274314A1 (en) 1974-06-12 1974-06-12 Incorporation of BCG into viral vaccines - in order to increase the immunising power of the vaccine

Country Status (1)

Country Link
FR (1) FR2274314A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309416A (en) * 1979-09-20 1982-01-05 Research Corporation Vaccines from taxonomically similar organisms

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309416A (en) * 1979-09-20 1982-01-05 Research Corporation Vaccines from taxonomically similar organisms

Also Published As

Publication number Publication date
FR2274314B1 (en) 1978-07-21

Similar Documents

Publication Publication Date Title
IL65875A0 (en) Capsules containing the active principle of an allergen,and process for their preparation
NZ218825A (en) Use of low dosages of interferon as adjuvants for vaccines
ZA91559B (en) Vaccines against cancer and infectious diseases
IT1119327B (en) IMPLANTABLE INFUSION DEVICE IN THE BODY OF THE PATIENT
HUT69803A (en) Porcine reproductive respiratory syndrome vaccine and diagnostic
RU96119793A (en) IMMUNOTHERAPEUTIC AGENT AND ITS APPLICATION
ES442892A1 (en) Feline calicivirus vaccine and production thereof
ES481108A1 (en) Inula extract, process for preparing it and its use as a medicament.
Filler et al. Tetanus prophylaxis
FR2274314A1 (en) Incorporation of BCG into viral vaccines - in order to increase the immunising power of the vaccine
ES8304058A1 (en) 3,7,11,15-Tetramethyl- 2,4,6,10,14-hexadecapentaenoic Acid
OA09863A (en) Use of IL-4 to enhance immune response to immunogens in vaccines.
FR2385401A1 (en) SYNCYTIAL RESPIRATORY VIRUS VACCINE
HUP9901299A2 (en) New indications for the use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses
HUP9700975A2 (en) Live attenuated rtx-producing bacteria of the family pasteurellaceae
Salvioli Killed anti-tuberculosis vaccine and hyaluronidase (diffusing vaccine)
SE7901863L (en) MEDICAL TREATMENT CHAIR, IN PARTICULAR DENTAL CHAIR
YAOI et al. TREATMENT OF WHOOPING COUGH BY COMBINED VACCINATION WITH H. PERTUSSIS VACCINE AND PURIFIED VACCINIA LYMPH (2)
YAOI et al. RESULT OF ACTIVE IMMUNIZATION AGAINST PERTUSSIS BY COMBINED H. PERTUSSIS VACCINE AND VACCINIA VIRUS, PERFORMED AT VILLAGES IN KANAGAWA PREFECTURE
Blatt et al. INTRADERMAL IMMUNIZATION: II. DIPHTHERIA
USD237728S (en) Toy beauty salon
FR2287912A1 (en) Sepharose type polysaccharides with amino-acid, pref glycine, gps - useful as non-specific immunity adjuvants for vaccines
Urguyev et al. Associated live vaccine against anthrax and blackleg.
ES2091307T3 (en) ASSOCIATIONS OF VACCINES AGAINST INFECTIOUS PATHOGENS.
USD237025S (en) Footstool

Legal Events

Date Code Title Description
ST Notification of lapse
ST Notification of lapse